

# Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment)

HealthTech guidance

Published: 30 March 2022

[www.nice.org.uk/guidance/htg619](https://www.nice.org.uk/guidance/htg619)

# Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

# Contents

Advice.....	4
-------------	---

This guidance replaces DG47.

## Advice

NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care. This is because data on the use of the assays in primary care has not been received. The assays are already recommended for use in [NICE's guideline on myeloma: diagnosis and management](#).

NICE will review the position if the company or any other stakeholder suggests the topic to NICE again.

ISBN: 978-1-4731-7388-0